Shinichi Makita

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

Koji Izutsu, Shinichi Makita, Kisato Nosaka et al. · Blood · 2022 · 156 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Clinicopathological features of histological transformation from extranodal marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue to diffuse large B‐cell lymphoma: an analysis of 467 patients

Akiko Miyagi Maeshima, Hirokazu Taniguchi, Kosuke Toyoda et al. · British Journal of Haematology · 2016 · 85 citations · Full text

Medicine, Hematology, Pathology +12

Oral histone deacetylase inhibitor tucidinostat (<scp>HBI</scp>‐8000) in patients with relapsed or refractory adult T‐cell leukemia/lymphoma: Phase <scp>IIb</scp> results

Atae Utsunomiya, Koji Izutsu, Tatsuro Jo et al. · Cancer Science · 2022 · 50 citations · Full text

Medicine, Oncology, Pharmacology +12

Expression pattern of <scp>PD</scp>‐L1 and <scp>PD</scp>‐L2 in classical Hodgkin lymphoma, primary mediastinal large B‐cell lymphoma, and gray zone lymphoma

Yosuke Tanaka, Akiko Miyagi Maeshima, Junko Nomoto et al. · European Journal Of Haematology · 2018 · 48 citations

Medicine, Oncology, Pathology +17

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma

Wataru Munakata, Yukari Shirasugi, Kensei Tobinai et al. · Cancer Science · 2021 · 31 citations · Full text

Medicine, Oncology, Pharmacology +15